ClinicalTrials.gg
Not yet recruitingNCT07414927Updated Feb 17, 2026

A Clinical Study for the Efficacy and Safety of BL0020 Injection in Patients With Small Cell Lung Cancer Transformed From Non-Small Cell Lung Cancer Following EGFR TKI Therapy

A Phase 1/2 interventional study of BL0020 in Small Cell Carcinoma of Lung, sponsored by Shanghai Best-Link Bioscience, LLC. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Shanghai Best-Link Bioscience, LLC · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Planned enrollment
208th of 333
48 · median 63
Started
2026
with 48 others
Phase 1/2
42 of 365
30 open now
Primary completion
2027-12
later than 133 of 214 live
Registered
330th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 208th largest by planned enrollment of the 333 interventional ones that give a count, is one of 49 that started in 2026, is one of 42 in phase 1/2, reaches primary completion later than 133 of the 214 other live ones, and was the 330th registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

The primary treatment option for non-small cell lung cancer (NSCLC) adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutation is EGFR tyrosine kinase inhibitor (TKI). After a certain period of treatment with EGFR TKI, acquired resistance emerges most frequently with a secondary mutation, p.T790M, followed by MET amplification. Interestingly, up to 3-14% of patients experience histological transformation into small cell lung cancer (SCLC), which has an aggressive clinical course and a poor prognosis.

The transformed SCLC retains the original EGFR mutation but significantly down regulates EGFR protein expression, eliminating its dependence on EGFR signaling while simultaneously acquiring a neuroendocrine phenotype. In nearly all cases, bi-allelic inactivation of both TP53 and RB1 is observed. However, little is known about the clinical outcomes of transformed SCLC, with limited studies arguing that their outcomes are similar to those of de novo SCLC, where the median overall survival is approximately 9 to 10 months after the transformation.

At present, there is no standard treatment regimen for patients with SCLC transformed from NSCLC following EGFR TKI therapy.

BL0020 is a polymer-drug conjugate consisting of Topoisomerase I inhibitor SN-38 (7-ethyl-10-hydroxycamptothecin) conjugated by a peptide linker to a PEG-modified poly(ε-L-lysine) polymer. In the ongoing first-in-human study of BL0020, significant efficacy has been observed with BL0020 monotherapy in SCLC patients who have relapsed or progressed following at least first-line platinum-based systemic treatment.

Based on previous clinical and preclinical outcomes that show similar disease characteristics between SCLC transformed from NSCLC following EGFR TKI therapy and de novo SCLC, this study is designed to evaluate the clinical efficacy and safety of BL0020 in patients with transformed SCLC.

03

Conditions studied

  • Small Cell Carcinoma of Lung
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteer to participate in the study, be able to understand the requirements of a clinical study, and willingness to sign a written form.
  2. Aged ≥ 18 years, male or female.
  3. Patients with initial diagnosis of EGFR-mutated NSCLC and or cytologically confirmed transformation to SCLC following treatment with EGFR tyrosine kinase inhibitor.
  4. After transformation to SCLC, the patient's prior treatment history must meet one of the following criteria:

    • Progression after only receiving platinum-based treatment regimens.
    • No prior systemic therapy for SCLC.
  5. (ECOG) performance status score 0 or 1 at screening.
  6. ≥ 12 weeks.

Exclusion criteria

Exclusion Criteria:

  1. Patients with symptomatic or carcinoma meningitis. Note:

    • Patients with treated brain metastases may participate in this study if the patient has completed radiotherapy or surgery for brain metastases ≥ 4 weeks prior to study entry, and neurologically stable ≥ 4 weeks after radiotherapy or surgery treatment [i.e., no new findings on brain imaging and no new neurologic deficits from brain metastasis on screening examination, and high doses of (> 10 mg prednisone daily or equivalent) were not required within 4 weeks prior to enrollment].
    • Patients with brainstem or spinal cord compression (detected by radiographic imaging, even if they did not have symptoms) were not eligible.
  2. Patients who have a history of another primary (with the exception of patients with cured basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ of uterine cervix). A patient who has had no evidence of disease from another primary cancer for 3 or more years is allowed to participate in the study.
  3. Patients with tumors that had invaded important blood vessels as shown in the screening imaging and that the investigators assessed were highly likely to cause fatal bleeding during the study.
  4. Patients whose pericardial effusion, pleural effusion or ascites remain uncontrollable after intervention.
  5. Patients with Gilbert's syndrome disease.
  6. Patients who have a known diagnosis of (HIV) infection or HIV antibody test positive during screening.
  7. Patients with active or chronic at screening ("active hepatitis" defined as HCV RNA level ≥ 200 IU/mL for hepatitis C or HBV DNA level ≥ 2000 IU/mL for hepatitis B at screening). In addition, eligible hepatitis B or hepatitis C patients must agree to antiviral treatment according to the treatment guidelines.
  8. Patients who have not sufficient baseline organ function.
  9. Those who are known to be allergic to the active ingredient or of the product BL0020 Injection, or who have a predisposition to allergy.
  10. Patients who are taking anticoagulant therapy (prophylactic use of low-dose aspirin [≤ 100 mg/day] or low molecular weight heparin is allowed).
  11. Those who have received live or attenuated vaccines (e.g., measles, mumps, rubella, varicella, yellow fever, rabies, BCG, typhoid vaccine, etc.) within 4 weeks before enrollment or scheduled to receive during the study.
  12. Pregnant or lactating women.
  13. Patients who are assessed disqualified to join clinical studies by investigator due to any causes.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    BL0020

    Drug: BL0020

Interventions

  • DrugBL0020

    BL0020 will be administered via intravenous infusion on Day 1 of each 21-day treatment cycle.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    ORR is defined as the proportion of patients with the best responses of Complete Response (CR) and Partial Response (PR) observed after study treatment

    Time frame: Throughout the study for approximately 2 years

Secondary outcomes

  1. Duration of response (DOR)

    DOR is defined as the time from the initial response (complete response \[CR\] or partial response \[PR\]) until first objective radiographic tumor progression or death from any cause

    Time frame: Throughout the study for approximately 2 years

  2. Disease control rate (DCR)

    DCR is the sum of complete response (CR), partial response (PR), and stable disease (SD) rates

    Time frame: Throughout the study for approximately 2 years

  3. Progression-free survival (PFS)

    PFS is defined as the time from the start date of study treatment until first objective radiographic tumor progression or death from any cause

    Time frame: Throughout the study for approximately 2 years

  4. Overall survival (OS)

    OS is defined as the time from the start date of study treatment until death from any cause

    Time frame: Throughout the study for approximately 2 years

  5. 3-Month Progression-Free Survival (PFS3)

    PFS3 is defined the proportion of patients who have not experienced first objective radiographic tumor progression or death due to any cause after 3 months from the start date of the study treatment

    Time frame: From the first study treatment to the 3-month time point

  6. 6-Month Progression-Free Survival (PFS6)

    PFS6 is defined the proportion of patients who have not experienced first objective radiographic tumor progression or death due to any cause after 6 months from the start date of the study treatment

    Time frame: From the first study treatment to the 6-month time point

  7. 9-Month Progression-Free Survival (PFS9)

    PFS9 is defined the proportion of patients who have not experienced first objective radiographic tumor progression or death due to any cause after 9 months from the start date of the study treatment

    Time frame: From the first study treatment to the 9-month time point

  8. 12-Month Progression-Free Survival (PFS12)

    PFS12 is defined the proportion of patients who have not experienced first objective radiographic tumor progression or death due to any cause after 12 months from the start date of the study treatment

    Time frame: From the first study treatment to the 12-month time point

  9. 6-Month Overall Survival rate (OS6)

    OS6 is defined the proportion of patients who are alive 6 months from the start date of the study treatment.

    Time frame: From the first study treatment to the 6-month time point

  10. 12-Month Overall Survival rate (OS12)

    OS12 is defined the proportion of patients who are alive 12 months from the start date of the study treatment

    Time frame: From the first study treatment to the 12-month time point

  11. Incidence of Treatment-Emergent Adverse Events (TEAEs)

    TEAEs are defined as those Adverse Events (AEs) with start or worsening date during the on-treatment period (from the first dose date of study treatment to 30 days after the last dose date of study treatment).

    Time frame: Throughout the study for approximately 2 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Dec 2027, 20 months later.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 20 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2026
First posted
Feb 17, 2026
StartEst.
Mar 27, 2026
Primary completionEst.
Dec 22, 2027
CompletionEst.
Feb 20, 2028
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07414927
Lead sponsor
Shanghai Best-Link Bioscience, LLC
Responsible party
Sponsor
First posted
Feb 17, 2026
Start date
Mar 27, 2026 (estimated)
Primary completion
Dec 22, 2027 (estimated)
Completion
Feb 20, 2028 (estimated)
Last update
Feb 17, 2026

Study contacts

Zhuolun Fang
Contact
fangzhuolun@bestlinkbio.com
+86 18357916536

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peptide-drug Conjugate BL0020

Start the discussion